Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$11.89
-0.78-6.16%
At close: -
$11.89
0.000.00%
After Hours: 4:01 PM EDT
Comments
Loading...
Bicara Therapeutics Analyst Ratings and Price Targets | NASDAQ:BCAX | Benzinga
Bicara Therapeutics Inc has a consensus price target of $29.67 based on the ratings of 7 analysts. The high is $47 issued by Stifel on October 8, 2024. The low is $8 issued by Wells Fargo on April 17, 2025. The 3 most-recent analyst ratings were released by Wells Fargo, HC Wainwright & Co., and Cantor Fitzgerald on April 17, 2025, April 7, 2025, and March 13, 2025, respectively. With an average price target of $21.67 between Wells Fargo, HC Wainwright & Co., and Cantor Fitzgerald, there's an implied 82.25% upside for Bicara Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Wells Fargo
HC Wainwright & Co.
Cantor Fitzgerald
Wedbush
Stifel
1calculated from analyst ratings
Analyst Ratings for Bicara Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/17/2025 | Buy Now | -32.72% | Wells Fargo | Eva Fortea Verdejo38% | → $8 | Initiates | → Underweight | Get Alert |
| 04/07/2025 | Buy Now | 270.06% | HC Wainwright & Co. | Robert Burns43% | $45 → $44 | Maintains | Buy | Get Alert |
| 03/13/2025 | Buy Now | 9.42% | Cantor Fitzgerald | Eric Schmidt33% | $13.01 → $13.01 | Reiterates | Overweight → Overweight | Get Alert |
| 02/12/2025 | Buy Now | 160.72% | Wedbush | David Nierengarten61% | $31 → $31 | Reiterates | Outperform → Outperform | Get Alert |
| 02/06/2025 | Buy Now | 160.72% | Wedbush | David Nierengarten61% | → $31 | Initiates | → Outperform | Get Alert |
| 01/27/2025 | Buy Now | 278.47% | HC Wainwright & Co. | Robert Burns43% | $42 → $45 | Maintains | Buy | Get Alert |
| 12/06/2024 | Buy Now | 253.24% | HC Wainwright & Co. | Robert Burns43% | → $42 | Initiates | → Buy | Get Alert |
| 10/08/2024 | Buy Now | — | Cantor Fitzgerald | Eric Schmidt33% | — | Initiates | → Overweight | Get Alert |
| 10/08/2024 | Buy Now | 295.29% | Stifel | Stephen Willey50% | → $47 | Initiates | → Buy | Get Alert |
| 10/08/2024 | Buy Now | 194.37% | Morgan Stanley | Judah Frommer66% | → $35 | Initiates | → Overweight | Get Alert |
| 10/08/2024 | Buy Now | — | TD Cowen | Tyler Van Buren46% | — | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Bicara Therapeutics (BCAX) stock?
The latest price target for Bicara Therapeutics (NASDAQ:BCAX) was reported by Wells Fargo on April 17, 2025. The analyst firm set a price target for $8.00 expecting BCAX to fall to within 12 months (a possible -32.72% downside). 11 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Bicara Therapeutics (BCAX)?
The latest analyst rating for Bicara Therapeutics (NASDAQ:BCAX) was provided by Wells Fargo, and Bicara Therapeutics initiated their underweight rating.
When was the last upgrade for Bicara Therapeutics (BCAX)?
There is no last upgrade for Bicara Therapeutics
When was the last downgrade for Bicara Therapeutics (BCAX)?
There is no last downgrade for Bicara Therapeutics.
When is the next analyst rating going to be posted or updated for Bicara Therapeutics (BCAX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Bicara Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Bicara Therapeutics was filed on April 17, 2025 so you should expect the next rating to be made available sometime around April 17, 2026.
Is the Analyst Rating Bicara Therapeutics (BCAX) correct?
While ratings are subjective and will change, the latest Bicara Therapeutics (BCAX) rating was a initiated with a price target of $0.00 to $8.00. The current price Bicara Therapeutics (BCAX) is trading at is $11.89, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
